35 related articles for article (PubMed ID: 37572583)
1. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing.
Wakuda K; Morita M; Sekikawa M; Morikawa N; Miura K; Doshita K; Iida Y; Kodama H; Mamesaya N; Kobayashi H; Ko R; Ono A; Kenmotsu H; Naito T; Murakami H; Muramatsu K; Kawata T; Mori K; Shimizu T; Gon Y; Takahashi T
Int J Clin Oncol; 2024 Feb; 29(2):96-102. PubMed ID: 38183554
[TBL] [Abstract][Full Text] [Related]
2. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
Liu Z; Wu Q; Li W; Li P; Huang L; Wang T; Zhou Q
Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
[TBL] [Abstract][Full Text] [Related]
3. Catalog of 5' Fusion Partners in
Ou SI; Zhu VW; Nagasaka M
JTO Clin Res Rep; 2020 Mar; 1(1):100015. PubMed ID: 34589917
[TBL] [Abstract][Full Text] [Related]
4. [ALK positive histiocytosis with multiple system involvement: report of a case].
Yao S; Zhang F; Chen Y; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):495-497. PubMed ID: 38678335
[TBL] [Abstract][Full Text] [Related]
5. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
[TBL] [Abstract][Full Text] [Related]
6. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
7. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
Ding Y; Sun C; Su W; Miao C; He X; Wang JS; Zhang ZH
Virchows Arch; 2022 Sep; 481(3):405-419. PubMed ID: 35624360
[TBL] [Abstract][Full Text] [Related]
8. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
Chen Y; Zhang X; Jiang Q; Wang B; Wang Y; Junrong Y
Lung Cancer; 2020 Aug; 146():370-372. PubMed ID: 32527613
[TBL] [Abstract][Full Text] [Related]
9. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel RSRC1-ALK (R6: A20) fusion using next-generation sequencing technique.
Xia J; Chen S; Zhang Z; Wang J
Cancer Genet; 2023 Nov; 278-279():18-23. PubMed ID: 37572583
[TBL] [Abstract][Full Text] [Related]
11. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]